Company profile for NuCana

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving survival outcomes for patients with cancer. We use our proprietary ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. Our highly experienced management team has a successful track record of building global, integrated biopharmaceutical compa...
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving survival outcomes for patients with cancer. We use our proprietary ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. Our highly experienced management team has a successful track record of building global, integrated biopharmaceutical companies and bringing life-saving oncology therapeutics to patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
3 Lochside Way Edinburgh EH12 9DT
Telephone
Telephone
+44 (0)131 357 1111
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-10-21/nucana-presents-encouraging-data-on-nuc-7738-in-combination-with-pd-1-inhibitors-using-primary-patient-derived-organoids-and-autologous-tumor-infiltra

PHARMIWEB
21 Oct 2025

https://www.pharmiweb.com/press-release/2025-10-15/nucana-announces-encouraging-data-for-nuc-3373-in-combination-with-anti-pd-1-therapy

PHARMIWEB
15 Oct 2025

https://www.pharmiweb.com/press-release/2025-09-04/nucana-to-present-data-on-nuc-7738-s-synergy-with-pd-1-inhibitors-at-the-esmo-congress-2025

PHARMAWEB
04 Sep 2025

https://www.fiercebiotech.com/biotech/another-nucanas-retooled-chemotherapies-unable-increase-survival-clinic

FIERCE BIOTECH
30 Aug 2024
NuCana's twist on chemo drug Gemzar fails in phase 3 again
NuCana's twist on chemo drug Gemzar fails in phase 3 again

09 Mar 2022

// N.P. Taylor FIERCEPHARMA

https://www.fiercepharma.com/drug-delivery/nucanas-twist-chemo-drug-gemzar-fails-phase-3-again

N.P. Taylor FIERCEPHARMA
09 Mar 2022

https://www.globenewswire.com/news-release/2022/02/22/2389768/0/en/NuCana-Announces-Enrollment-of-Required-Number-of-Patients-to-Conduct-Second-Interim-Analysis-in-the-Phase-III-Biliary-Tract-Cancer-Study.html

GLOBENEWSWIRE
22 Feb 2022

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty